Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
32825 | 102 | 22.2 | 48% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
2348 | 3955 | PHOSPHOLIPIDOSIS//2 DEOXYSTREPTAMINE//AMINOGLYCOSIDES |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | HYBRIDIZATION TECHNOLOGY | Author keyword | 1 | 100% | 2% | 2 |
2 | IMMUNOLIGAND ASSAY | Author keyword | 1 | 100% | 2% | 2 |
3 | BIOASSAY GRP | Address | 1 | 50% | 1% | 1 |
4 | CAS 105857 23 6 | Author keyword | 1 | 50% | 1% | 1 |
5 | E COLI HOST CELL PROTEINS | Author keyword | 1 | 50% | 1% | 1 |
6 | ESCHERICHIA COLI ANTIGEN | Author keyword | 1 | 50% | 1% | 1 |
7 | ANTI BACTERIUM | Author keyword | 0 | 33% | 1% | 1 |
8 | CLINICAL CONSIDERATIONS | Author keyword | 0 | 33% | 1% | 1 |
9 | PROTEIN PHARMACEUTICAL | Author keyword | 0 | 33% | 1% | 1 |
10 | SYMBIOFLOR R 1 | Author keyword | 0 | 33% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BIOTECHNOLOGY PRODUCT VALIDATION | 0 | 25% | 1% | 1 |
2 | HEPATITIS B VACCINES | 0 | 13% | 2% | 2 |
3 | PROTEIN IMPURITIES | 0 | 20% | 1% | 1 |
4 | THERAPEUTIC PRODUCTS | 0 | 13% | 1% | 1 |
5 | PASSIVELY ADMINISTERED ANTIBODY | 0 | 11% | 1% | 1 |
6 | TETANUS TOXIN ANTIGEN | 0 | 11% | 1% | 1 |
7 | BIOASSAY DEVICE | 0 | 100% | 1% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
FDA regulatory reform | 1997 | 3 | 3 | 67% |
Progress in the use of biological assays during the development of biotechnology products | 2001 | 13 | 21 | 24% |
IMPROVEMENT AND EXPERIMENTAL VALIDATION OF PROTEIN IMPURITY IMMUNOASSAYS FOR RECOMBINANT-DNA PRODUCTS | 1990 | 7 | 14 | 36% |
MANUFACTURE OF BIOPHARMACEUTICAL PROTEINS BY MAMMALIAN-CELL CULTURE SYSTEMS | 1990 | 2 | 4 | 50% |
VIRUS-VACCINES - 1986 UPDATE | 1986 | 5 | 1 | 100% |
SENSITIVE DETECTION AND QUANTITATION OF PROTEIN CONTAMINANTS IN RDNA PRODUCTS | 1988 | 0 | 6 | 67% |
BIOSAFETY CONSIDERATIONS IN INDUSTRIES WITH PRODUCTION METHODS BASED ON THE USE OF RECOMBINANT DEOXYRIBONUCLEIC-ACID | 1990 | 4 | 17 | 12% |
DEVELOPING RESEARCH TRENDS IN THE CHEMISTRY OF PLANT-RESISTANCE TO PESTS | 1986 | 2 | 7 | 29% |
Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens | 2005 | 27 | 109 | 3% |
NEW BIOTECHNOLOGY AS A LOGICAL OUTGROWTH OF MOLECULAR-BIOLOGY | 1986 | 1 | 50 | 8% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BIOASSAY GRP | 1 | 50% | 1.0% | 1 |
2 | BIOL EVALUAT CYTOKINE BIOL | 0 | 25% | 1.0% | 1 |
3 | BAMD GRP | 0 | 100% | 1.0% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000248041 | TROSPECTOMYCIN//CLIN SCI AGR PRACTICES//ANAEROBIC SUSCEPTIBILITY |
2 | 0.0000096658 | SALMONELLA ZENTRALE//URIDINE DIPHOSPHOGLUCURONYL TRANSFERASE//BUNDES INFEKTIONSKRANKHEITEN NICHT UBERTRAG |
3 | 0.0000093878 | NASAL AIRFLOW//SAUL A SILVERMAN FAMILY FDN//VA1 RNA |
4 | 0.0000092624 | FOOD CONTACT REGULATION//TOXICITY ASSESSMENT OF TREATED WASTEWATER//EEC DIRECTIVES |
5 | 0.0000086715 | BOVINE HIPPOCAMPUS//SEROTONIN1A RECEPTOR//P MPPF |
6 | 0.0000080293 | 20K HGH//22K HGH//GH ABUSE |
7 | 0.0000076833 | ALTERNATING POISSON PROCESS//ALTERNATING RENEWAL//PRODUCTION CYCLE TIME |
8 | 0.0000075320 | RALSTONIA PICKETTII//BREVUNDIMONAS DIMINUTA//FILTER VALIDATION |
9 | 0.0000072800 | CO OPERATIVE GOVERNMENT//CONSTITUTIONAL SUPREMACY//HOUSING DERIVATIVES |
10 | 0.0000062368 | TGN1412//SAFETY PHARMACOLOGY//REPEAT DOSE TOXICITY STUDIES |